REVAGENIX INC - A NOVEL LPXC INHIBITOR WITH PAN-RESISTANT PSEUDOMONAS AND BURKHOLDERIA ACTIVITY.

On Dec 30, 2025, Department of Health and Human Services obligated $17,883,175 to REVAGENIX INC for a novel lpxc inhibitor with pan-resistant pseudomonas and burkholderia activity.. The award is classified under NAICS 541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) and issued as a cost plus fixed fee contract. Competition extent: full and open competition with 30 offers received. The procurement used a NO SET ASIDE USED. set-aside. Performance is located in SAN MATEO, CA. The contract is scheduled through Sep 30, 2026 — approximately 5 months remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541715 — related awards are listed below.